Zobrazeno 1 - 4
of 4
pro vyhledávání: '"27-78"'
Autor:
Higham CE; Department of Endocrinology, Christie Hospital, Manchester, UK., Chung TT, Lawrance J, Drake WM, Trainer PJ
Publikováno v:
Clinical endocrinology [Clin Endocrinol (Oxf)] 2009 Jul; Vol. 71 (1), pp. 86-91. Date of Electronic Publication: 2008 Nov 05.
Autor:
Parkinson C; Department of Diabetes and Endocrinology, The Ipswich Hospital, Suffolk, UK. craig.parkinson@ipsh-tr.anglox.nhs.uk, Whatmore AJ, Yates AP, Drake WM, Brabant G, Clayton PE, Trainer PJ
Publikováno v:
Clinical endocrinology [Clin Endocrinol (Oxf)] 2003 Aug; Vol. 59 (2), pp. 168-74.
Publikováno v:
Clinical Endocrinology. 71:86-91
Summary Aims To evaluate the long-term efficacy and safety of pegvisomant as a treatment for acromegaly. Design Retrospective analysis of clinical and trial data from all patients treated with pegvisomant since 1997 at two centres with common protoco
Publikováno v:
Clinical endocrinology. 59(2)
In humans, serum leptin correlates positively with fat mass. GH is lipolytic and patients with active acromegaly have lowered serum leptin compared to age, sex and body mass index (BMI)-matched controls, but a direct influence of GH on serum leptin r